Treatment with either cabozantinib or MVA/rF-CEA/TRICOM alone reduced the percentage of infiltrating tumor-associated macrophages (TAMs) (P =0.01–0.005), but again, the combination further reduced TAM infiltration (Figure 5C). This evidence concerns the gene CEACAM5 and neoplasm.